Clinical Trial: Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence

U.S., May 2 -- ClinicalTrials.gov registry received information related to the study (NCT06954116) titled 'Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence' on April 09.

Brief Summary: The purpose of this study is to evaluate the impact of iparomlimab and tuvonralimab as preoperative neoadjuvant therapy on recurrence-free survival (RFS), along with its potential improvement in overall survival (OS), in patients with resectable hepatocellular carcinoma (HCC) at high risk of recurrence.

Study Start Date: June 15

Study Type: INTERVENTIONAL

Condition: Resectable Hepatocellular Carcinoma With High Risk of Recurrence

Intervention: DRUG: Iparomlimab and Tuvonralimab (QL...